This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Tardive dyskinesia

Authoring team

Tardive dyskinesia is characterised by oral grimaces with chewing and sucking movements - oro-facial dyskinesia. There are also choreo-athetoid movements of the upper limbs. The movements disappear during sleep.

Although symptoms are typically not painful, they may impede social interaction and cause difficulty in chewing, swallowing, and talking.

Tardive dyskinesia may occur after neuroleptic treatment; the risk of it developing rises with increasing age and prolonged exposure to the offending drug. A cohort study involving 261 patients aged over 55 years and previously untreated with conventional antipsychotic drugs, revealed that the cumulative rates of tardive dyskinesia were 25% after 1 year and 53% after 3 years cumulative exposure to conventional antipsychotics (1)

  • tardive dyskinesia is more common in females
  • increased incidence and severity of tardive dyskinesia appear to be positively associated with the number of medication-free periods (2)
    • mechanism responsible for this effect is unclear, but may involve the impact of the medication-free periods on the D1-mediated striato-nigral pathway
  • incidence of tardive dyskinesia is substantially greater in patients treated with conventional rather than atypical antipsychotic agents

After drug withdrawal, dyskinesias disappear over a period of 3 years in 60% of patients. However, the remainder have persistent symptoms. There is no response to anti - parkinsonian drugs (may make symptoms worse). Other extrapyramidal complications of phenothiazine therapy (e.g. drug-induced parkinsonism, acute dystonia, akathisia) tend to respond rapidly to phenothiazine withdrawal or to anticholinergic medication.

This condition is thought to occur because of an increase in the number of dopamine receptors.

The symptoms can initially be alleviated by increasing the dose of the anti-psychotic drug but this will worsen the condition in the long term.

Reference:

  1. Drug and Therapeutics Bulletin 2003; 41 (1): 1-4.
  2. Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-Induced Tardive Dyskinesia: A Review and Update. Ochsner J. 2017 Summer;17(2):162-174.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2026 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.